Oppenheimer Asset Management Inc. Sells 17,874 Shares of Smith & Nephew SNATS, Inc. $SNN

Oppenheimer Asset Management Inc. trimmed its stake in Smith & Nephew SNATS, Inc. (NYSE:SNN) by 28.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 45,440 shares of the medical equipment provider’s stock after selling 17,874 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Smith & Nephew SNATS were worth $1,649,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of SNN. Bank of Montreal Can lifted its position in Smith & Nephew SNATS by 321.6% in the second quarter. Bank of Montreal Can now owns 3,429,829 shares of the medical equipment provider’s stock worth $105,056,000 after buying an additional 2,616,301 shares during the last quarter. Yousif Capital Management LLC bought a new position in Smith & Nephew SNATS during the second quarter valued at $217,000. Allspring Global Investments Holdings LLC raised its stake in shares of Smith & Nephew SNATS by 4.8% in the second quarter. Allspring Global Investments Holdings LLC now owns 12,462 shares of the medical equipment provider’s stock valued at $381,000 after acquiring an additional 570 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Smith & Nephew SNATS by 6,663.4% in the second quarter. JPMorgan Chase & Co. now owns 1,210,655 shares of the medical equipment provider’s stock valued at $37,082,000 after acquiring an additional 1,192,755 shares during the period. Finally, Saturna Capital Corp bought a new stake in shares of Smith & Nephew SNATS in the 2nd quarter worth about $312,000. Hedge funds and other institutional investors own 25.64% of the company’s stock.

Smith & Nephew SNATS Trading Up 1.8%

Shares of NYSE:SNN opened at $36.16 on Friday. Smith & Nephew SNATS, Inc. has a 52-week low of $23.91 and a 52-week high of $38.79. The business’s 50 day moving average is $33.48 and its 200 day moving average is $34.77. The company has a debt-to-equity ratio of 0.60, a current ratio of 3.00 and a quick ratio of 1.40.

Analyst Upgrades and Downgrades

SNN has been the topic of several analyst reports. Kepler Capital Markets upgraded shares of Smith & Nephew SNATS to a “strong-buy” rating in a report on Monday, November 17th. Canaccord Genuity Group dropped their target price on Smith & Nephew SNATS from $36.00 to $34.00 and set a “hold” rating for the company in a research report on Tuesday, November 11th. Wall Street Zen raised Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 10th. Royal Bank Of Canada downgraded Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a report on Monday, December 15th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Smith & Nephew SNATS has an average rating of “Hold” and an average price target of $35.75.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.